Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early adopter of SC daratumumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Gordon, Ashcroft, John, Fernandez, Mariana, Henshaw, Sarah, Khalaf, Zeyad, Pratt, Guy, Tailor, Anish, Rabin, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996301/
https://www.ncbi.nlm.nih.gov/pubmed/36910662
http://dx.doi.org/10.3389/fonc.2023.1063144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996301/
https://www.ncbi.nlm.nih.gov/pubmed/36910662
http://dx.doi.org/10.3389/fonc.2023.1063144

Ejemplares similares